We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+17.41%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$17.6M
Cap. Flow
-$3.26M
Cap. Flow %
-0.82%
Top 10 Hldgs %
70.4%
Holding
40
New
10
Increased
13
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$28.6M
2
GILD icon
Gilead Sciences
GILD
+$22.5M
3
BIVV
Bioverativ Inc. Common Stock
BIVV
+$16.9M
4
SNY icon
Sanofi
SNY
+$12.9M
5
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$12.7M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.3M
2
SHPG
Shire pic
SHPG
+$33.5M
3
AGN
Allergan plc
AGN
+$33.3M
4
TSRO
TESARO, Inc.
TSRO
+$19.1M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
26
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.85M 0.72%
574,797
+23,800
+4% +$229K
RCKT icon
27
Rocket Pharmaceuticals
RCKT
$355M
$1.7M 0.43%
213,006
+109,900
+107% +$739K
VXRT
28
DELISTED
Vaxart
VXRT
$1.13M 0.29%
156,834
-4,518
-3% -$46.2K
CNC icon
29
Centene
CNC
$31.6B
– –
-293,200
Closed -$8.28M
ESPR
30
DELISTED
Esperion Therapeutics
ESPR
– –
-364,000
Closed -$4.56M
LLY icon
31
Eli Lilly
LLY
$1.07T
– –
-547,405
Closed -$40.3M
PRTK
32
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-124,519
Closed -$1.92M
AERI
33
DELISTED
Aerie Pharmaceuticals
AERI
– –
-188,900
Closed -$7.15M
TVTY
34
DELISTED
Tivity Health, Inc. Common Stock
TVTY
– –
-383,200
Closed -$8.72M
MNK
35
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-306,500
Closed -$15.3M
AGN
36
DELISTED
Allergan plc
AGN
– –
-158,700
Closed -$33.3M
TSRO
37
DELISTED
TESARO, Inc.
TSRO
– –
-142,300
Closed -$19.1M
AAAP
38
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-14,400
Closed -$385K
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
– –
-158,100
Closed -$1.92M
SHPG
40
DELISTED
Shire pic
SHPG
– –
-196,400
Closed -$33.5M
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Senzar Asset Management held 40 positions worth $395M, up 4.7% from $377M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Senzar Asset Management's Q1 2017 filing shows 10 new, 13 increased, 5 reduced and 12 closed positions. Its largest new stake was Gilead Sciences: 320,600 shares worth $21.8M. The largest sale was Eli Lilly, an estimated $40.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier.

  • Senzar Asset Management's largest Q1 2017 buy was Gilead Sciences: 320,600 shares worth $21.8M.
  • Senzar Asset Management added most to Halozyme in Q1 2017, an estimated $28.6M increase.
  • Senzar Asset Management's biggest Q1 2017 reduction was Elevance Health, cutting an estimated $7.17M.
  • Senzar Asset Management fully exited Eli Lilly in Q1 2017, selling an estimated $40.3M.
  • Senzar Asset Management's ten largest holdings make up 70% of its $395M portfolio in Q1 2017.
  • Senzar Asset Management opened 10 new positions and closed 12 in Q1 2017.
  • Senzar Asset Management's portfolio value rose 4.7% quarter-over-quarter to $395M.

Based on Senzar Asset Management's 13F filing for Q1 2017, filed 12 May 2017.